U.S. flag

An official website of the United States government

PMC Full-Text Search Results

Items: 3

1.
Figure 2

Figure 2. From: ALLOPURINOL DOES NOT DECREASE BLOOD PRESSURE OR PREVENT THE DEVELOPMENT OF HYPERTENSION IN THE DOCA-SALT RAT MODEL.

A. Study design for allopurinol effects on the development of DOCA-salt hypertension (long-term administration). B. Blood pressure of vehicle (closed symbols) and allopurinol (open symbols)-treated rats, measured by radiotelemetry. Timing of interventions is represented by vertical lines. Data are represented as means ± SEM of 24h average mean arterial pressure (MAP) for N=6.

Theodora Szasz, et al. J Cardiovasc Pharmacol. ;56(6):627-634.
2.
Figure 1

Figure 1. From: ALLOPURINOL DOES NOT DECREASE BLOOD PRESSURE OR PREVENT THE DEVELOPMENT OF HYPERTENSION IN THE DOCA-SALT RAT MODEL.

A. Study design for allopurinol effects on established DOCA-salt hypertension (short-term administration). B. Blood pressure of vehicle (closed symbols) and allopurinol (open symbols)-treated rats, measured by radiotelemetry. Timing of interventions is represented by vertical lines. Data are represented as means ± SEM of 24h average mean arterial pressure (MAP) for N=4.

Theodora Szasz, et al. J Cardiovasc Pharmacol. ;56(6):627-634.
3.
Figure 3

Figure 3. From: ALLOPURINOL DOES NOT DECREASE BLOOD PRESSURE OR PREVENT THE DEVELOPMENT OF HYPERTENSION IN THE DOCA-SALT RAT MODEL.

Hemodynamic parameters: systolic blood pressure (A), diastolic blood pressure (B), pulse pressure (C), and heart rate (D) of DOCA-salt hypertensive rats under long-term treatment with vehicle (closed symbols) and allopurinol (open circles). The vertical line represents the initiation of vehicle or allopurinol treatment. Data are represented as means ± SEM of 24h averages (MAP) for N=6.

Theodora Szasz, et al. J Cardiovasc Pharmacol. ;56(6):627-634.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Support Center